Kornimate/medical-research-clean huggingface dataset:
thrombosis risk assessment and clinical presentation of covid-19 pneumonia

Conditions: Corona Virus Infection; Thromboembolic Disease

Summary: covid-19 mainly affects the respiratory system. multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. in this study, the association between thrombosis risk and clinical presentation of covid-19 is investigated.

the severe acute respiratory distress syndrome related coronavirus-2 (sars-cov-2) and its clinical presentation as coronavirus disease 2019 (covid-19) was first reported in wuhan, hubei, china in december 2019. it has spread rapidly from its origin in wuhan city to other countries of the world over the last several months. although it mainly affects the respiratory system , multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. sars-cov-2 infection may also lead to thrombotic disease both in the venous and arterial circulation of patients apart from respiratory system due to excessive inflammation, thrombocyte activation, endothelial malfunction, and stasis. investigators have reported that both chads2 and cha2ds2-vasc scores were related to mortality in individuals that had stable coronary angina, acute coronary syndrome, takotsubo syndrome or sick sinus syndrome, apart from atrial fibrillation . in addition, thrombocyte/lymphocyte (plt/lym) and neutrophil/lymphocyte (neu/lym) ratios on admission were also related with thromboembolic complications in former studies which found them useful to predict prognosis of acute pulmonary embolism, as being one of the thromboembolic complications of covid-19. investigators suggest that the parameters mentioned above should also be studied in terms of thrombotic complications of covid-19. thus they aimed to find out potential associations between markers of prothrombotic or inflammatory conditions and some clinical features of covid-19 pneumonia cases on admission and follow-up.

Eligibility criteria:
inclusion criteria: * patients diagnosed with covid - 19 pneumonia between march 11 th , 2020 and april 25th, 2020 in the emergency, internal medicine and cardiology outpatient clinics. * patients diagnosed by pcr testing and computed tomography of the chest exclusion criteria: * patients below 18 years of age * patients with an alternative aetiology of pneumonia

Keywords: covid-19 pneumonia thromboembolism risk length of hospitalization
medtronic south asian systolic heart failure registry

Conditions: Heart Failure

Summary: the purpose of this study is to (a) characterize the current management of patients with systolic heart failure (hf) in south asia following an educational intervention of current guidelines and delivery of disease management tools and (b) to characterize the effect of current therapy on clinical outcomes in patients managed by tertiary care centers across south asia. current therapy includes characterization of the post market performance of any market released medtronic cardiac resynchronization therapy (crt) or cardiac resynchronization therapy plus implantable cardiac defibrillator (crt-d) system for cardiac resynchronization therapy (crt).


Eligibility criteria:
inclusion criteria: * patient has signed and dated study informed consent. patients having moderate to severe heart failure (nyha class iii or iv) ef \ 120 ms. exclusion criteria: patient has life expectancy of less than 12 months due to medical conditions other than hf. * patient has experienced unstable angina, acute myocardial infarction (mi), coronary artery bypass graft (cabg) or percutaneous transluminal coronary angioplasty (ptca) within the past 3 months. * patient is known to have chronic permanent atrial arrhythmias (i.e., cases of long-standing atrial fibrillation of greater than 1 year, including those in which cardioversion has not been indicated or attempted). * patient is enrolled in any concurrent study that would confound the results of this study. * patient is pregnant or breastfeeding. * patient has a crt device implanted previously. * patient has had a heart transplant.

Keywords: cardiac resynchronization therapy moderate to advanced patients current consensus guidelines
study evaluating the safety, tolerability, and efficacy of switching from quetiapine to ziprasidone

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.


Eligibility criteria:
inclusion criteria: * males or females, between 18 and 55 years of age, at the time of consent. * subjects must have a primary diagnosis of schizophrenia, any subtype (code 295.xx), or schizoaffective disorder as defined in dsm-iv-tr (diagnostic and statistical manual of mental disorders - fourth edition) * subjects must have normal vital signs, physical examination, ecg, and laboratory findings except for minor deviations determined and documented to be clinically insignificant by the investigator or a sub-investigator who is a medical doctor. exclusion criteria: * subjects who are unable to provide informed consent * subjects who meet criteria for a dsm-iv-tr axis i (diagnostic and statistical manual of mental disorders - fourth edition) diagnosis other than schizophrenia or schizoaffective disorder, including psychoactive substance abuse or dependence within one year of study entry * females who are pregnant, breast feeding, or lactating at screening.

Keywords: ziprasidone, quetiapine (seroquel) switch, open label, flexible dose, schizophrenia, schizoaffective disorder
the research of the cerebral protection effects of electroencephalogram (sedline) during carotid endarterectomy

Conditions: Transient Ischemic Attack; Acute Stroke; Postoperative Delirium; Postoperative Cognitive Dysfunction

Summary: fragile brain is the most common phenomenon seen in the patients undergoing cea. the patients with fragile brain have a high incidence of postoperative brain dysfunction. this study intends to apply eeg monitoring (sedline) to cea to investigate whether eeg monitoring can reduce the incidence of postoperative neurological complications in cea patients and improve their prognosis. 220 patients with cea were randomly divided into 2 groups. group s \[sedline monitoring + transcranial doppler (tcd) + regional cerebral oxygen saturation (rs02)，n=110\] and group c \[bispectral index (bis)/sedline monitoring + tcd +rso2,n=110\], recording intraoperative and postoperative conditions, neuropsychology scale assessment, blood examination and imaging examination. the incidence of postoperative neurological complications was compared between the two groups.


Eligibility criteria:
inclusion criteria: 1. patients undergoing elective carotid endarterectomy; 2. all those who agree to join the trial and sign the informed consent form; 3. asai to iii. exclusion criteria: 1. those who refuse to sign the informed consent form; 2. asa level iv and above; 3. unstable angina or acute myocardial infarction within 4 to 6 weeks before surgery, and heart function nyha iii to iv; 4. those with severe liver and kidney function diseases; 5. preoperative combined cognitive impairment; \[mmse reference demarcation value: illiterate (uneducated) group ≤ 19 points, primary school (education years ≤ 6 years) group ≤ 22 points, secondary school or above (education years) 6 years) group ≤26 points; moca reference demarcation value: illiterate ≤13, primary school ≤19, middle school and above ≤24. \] 6. preoperative combined anxiety and depression; (sds or sas\>41 points) 7. patients with an endotracheal intubation returning to the icu; 8. severe allergic reactions, major bleeding, etc. during surgery, causing severe fluctuations in hemodynamics; 9. the subject actively requested to withdraw from the study or to be lost to follow-up.
alknee follow-up study of the cementless attune rotating platform and the cementless lcs rotating platform knee system

Conditions: Total Knee Arthroplasty; Total Knee Replacement; Knee Osteoarthritis

Summary: the cementless attunetm rotating platform knee system was compared in a single-blind, randomized rsa trial to its predecessor, the lcs rotating platform knee system. in this previous study, 61 knees were subjected to rsa examinations at 1-day and 3, 6, 12 and 24 months postoperative. this study found a promising equal migration of both tibial components and a lesser migration of the femoral component of the attunetm knee system after two years, although with a similar migration rate between year 1 and 2. this raises the question of whether the migration of the prostheses relative to each other will increase or remain the same in the long term. to examine this, a mid-and long-term rsa follow-up to measure migration is necessary. in addition, another new rsa measurement parameter has become known in recent years that may provide an indication of the bonding of the prosthesis to the bone at the time of measurement. this new parameter, called the induced displacement (id) of a prosthesis, measures the position and orientation relative to the bone while the prosthesis is under different loading conditions (e.g., patient in supine or standing position). this means that a large measured difference between these different loading condition measurements would indicate that osseointegration of the prosthesis never occurred or is no longer present. to improve the understanding of the tendency of both prostheses to aseptic loosening after a mid- to long-term follow up, migration over time and inducible displacement analyses are necessary. the primary objective of this study is to accurately compare mid- and long-term migration of two uncemented tkr prostheses. the secondary objectives of this study are to evaluate if inducible displacement can be used as a parameter to detect loose implants, and to compare inducible displacement, clinical and radiological outcome and patient-reported outcomes (proms) after a follow-up of 5 and 10 years of two uncemented tkr prostheses.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria: * the patient participated in the initial study (nl58911.058.16) \[1\]. * the patient is capable of giving informed consent and expressing a willingness to comply with the study. exclusion criteria: a potential subject who meets any of the following criteria will be excluded from participation in this study: * the patient underwent a major revision tkr (exchange of the tibial or femoral component). * the patient is unable or unwilling to sign the informed consent specific to this study.
median nerve hydro-dissection using single injection of hyalase as a novel treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Pain, Chronic

Summary: carpal tunnel syndrome (cts) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline of the median nerve could offer symptoms and clinical improvement

carpal tunnel syndrome (cts) is the most common compression syndrome the upper extremities. its problem has a high prevalence ranged estimated prevalence of 3.8% in the general population, 3 and 7.8% in the working population. it occurs at any age, especially in individuals in their 40s to 60s, and the male: female ratio is reported to be 3:7. a lot of treatment modalities have been tried to improve the condition, starting from local anesthetic injection, steroid, and up to surgical decompression of the nerves.

Eligibility criteria:
inclusion criteria: * adult patients * complaining of carpal tunnel syndrome of 3 month duration or more * diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study exclusion criteria: * patient refusal infection at the site of intervention * local anesthetic allergy
aml96 - risk-adapted and randomized postremission-therapy for adult acute myeloid leukemia patients

Conditions: Leukemia, Nonlymphoblastic, Acute

Summary: the aml96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk aml patients and related allogeneic and autologous stem cell transplantation for standard risk aml patients in a multi-center setting. furthermore it randomizes patients between intermediate-dose cytarabine vs high-dose cytarabine within the first postremission-course.

the aml96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk aml patients and related allogeneic and autologous stem cell transplantation for standard risk aml patients in a multi-center setting. furthermore it randomizes patients between intermediate-dose cytarabine vs high-dose cytarabine within the first postremission-course.

Eligibility criteria:
inclusion criteria: * de novo or secondary acute myeloid leukemia of the fab subtypes m0-m2 and m4-m7 * de novo or secondary myelodysplastic syndrome fab subtypes raeb and raeb-t * written informed consent exclusion criteria: * severe comorbidities * severe uncontrolled complications of the leukemia * previous therapy of leukemia/mds * hiv-infection * known relevant allergy against study medication * pregnancy * missing written informed consent

Keywords: acute myeloid leukemia cytarabine postremission dosage risk adapted treatment strategy allogeneic stem cell transplantation autologous stem cell transplantation
evaluation of prognostic monitoring for women who have completed standard treatment for ovarian cancer

Conditions: Ovarian Cancer

Summary: the relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

100 cases in normal ovarian control group, 100 cases in benign ovarian disease group and 100 cases in malignant ovarian epithelial carcinoma group will be studied. change regularity of ovarian cancer specific immune inflammation-related protein complexes in blood will be studied. the relationship between disease-specific protein complexes and pathological state of patients will be analyzed.

Eligibility criteria:
inclusion criteria: * female * normal ovary control * ovarian benign disease * ovarian malignant epithelial carcinoma exclusion criteria: * male * age above 70 * suffering from other malignant tumors * non-compliant patient
infusion treatments of chronic peripheral neuropathic pain

Conditions: Neuropathic Pain

Summary: this study aimed to evaluate and compare the efficacy of ketamine and lidocaine infusion in patients with chronic peripheral neuropathic pain. patients who received intravenous ketamine infusion and the other patient group who received intravenous lidocaine infusion were evaluated in the study. pain scores and quality of life were assessed with scales before treatment at two weeks, two months, and six months after treatment.

this study, it was aimed to evaluate and compare the efficacy of intravenous infusion of ketamine and lidocaine, which have been known and used in pain management and which have recently increased interest in the treatment of peripheric neuropathic pain.

Eligibility criteria:
inclusion criteria: * 18-65 years of age * patients with peripheral neuropathic pain (radicular neuropathy, diabetic neuropathy, complex regional pain syndrome type 2, traumatic peripheral nerve injury, trigeminal neuralgia, postherpetic neuralgia) * patients who was evaluated by dn4 scores with of ≥4 points exclusion criteria: * patients with central nervous system disease . * patients with cancer related neuropatic pain. * patients with central neuropathic pain patterns. * patients with renal, hepatic, cardiovascular, and psychiatric diseases. * patients whose treatment could not be completed due to side effects or other reasons. * patients who had lost their follow-up .

Keywords: lidocaine ketamine pain measurement, scale
the impact of transanal decompression tube placement after colorectal anastomosis: a randomized trial

Conditions: Colorectal Cancer; Postoperative Complications; Anastomotic Leak; Anastomotic Complication

Summary: there is currently no standardization in the use of the transanal decompressive tube during the postoperative after a colorectal surgery. the available evidence is based on studies with methodological differences. most of the studies exclude patients with a diverting ileostomy, which are those patients who have a higher risk of anastomotic leak, so the real effect of transanal decompressive tube could have been masked. for this reason we believe that to assess the true effect of rectal decompression, patients with diverting stoma should be included.

one of the complications of performing the colorectal anastomosis is the anastomotic leak, which sometimes entails the need for reinterventions and stoma formation (provisional or definitive). in recent decades, the improvement in surgical techniques together with the knowledge of the causes that predispose to the anastomotic failure have allowed to reduced the rates. the placement of a tube probe through the anus in the postoperative period that decompresses the contents of the interior of the intestine (liquid or air) has been proposed as a factor that could influence the healing between intestines. in studies carried out in other centers, with the same characteristics as the present one, differences have been shown in the probability of anastomotic leakage, but these results are not conclusive and do not allow us to know the effectiveness of this procedure.

Eligibility criteria:
inclusion criteria: * patients undergoing scheduled laparoscopic, robotic or laparotomic colorectal cancer surgery who undergo colorectal anastomosis. * both mechanical and manual colorectal anastomosis with or without diverting ileostomy. * negative intraoperative air-leak test. * height of the anastomosis: promontory or distal to it. * age≥18 years. * histology of adenocarcinoma with or without prior neoadjuvant treatment. * any t, any n, any m. * informed consent signed by the patient and by the researcher. exclusion criteria: * no performance of colorectal anastomosis. * colorectal tumor with histology other than adenocarcinoma or adenoma. * patients with psychiatric illnesses, addictions or any disorder that prevents understanding of surgery. * inability to read or understand any of the informed consent languages (catalan, spanish). * emergency surgery. * any patient who, due to his medical characteristics, presents a high individual risk when being included and completing the study.

Keywords: colorectal cancer transanal tube emplacement anastomotic leakage
transcranial direct current stimulation (tdcs) for treatment-resistant obsessive-compulsive disorder (front)

Conditions: Obsessive-Compulsive Disorder

Summary: neuromodulation techniques for the treatment of obsessive-compulsive disorder (ocd) have expanded with the greater understanding of the brain circuits involved in this disorder. transcranial direct current stimulation (tdcs) is a non-invasive neuromodulation technique that has been studied as an alternative for strategy for treatment-resistant ocd. the main study is a randomized, sham-controlled, double-blinded trial tdcs for ocd patients unresponsive to cognitive-behavioral therapy and/or selective serotonin reuptake inhibitors. forty-four patients will be randomized to two groups: active or simulated intervention. the intervention consisted of delivering an electric current of 2ma to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, and the anode positioned in the deltoid (neutral region), during 30-minutes, for four consecutive weeks. the primary outcome was the reduction in baseline ybocs scores before and after of tdcs treatment. secondary outcomes include measures of depressive and anxiety symptoms, genetic markers, motor cortical excitability and performance in neurocognitive tests.


Eligibility criteria:
inclusion criteria: * patients diagnosed with ocd according to dsm iv criteria * ybocs score of 16 and above or ≥10 (for the presence of only compulsions or only obsessions) * patients with other psychiatric comorbidities are not excluded, however, ocd should be the most important disease . * age between 18 and 65 * patients who failed one or more treatments * patients with no previous treatment for ocd will be treated with one first line treatment before being considered to participate in the tdcs trial. * voluntary and competent to consent exclusion criteria: * other diagnostic axis i whose treatment take precedence over the treatment of ocd (bipolar affective disorder; dependence alcohol; schizophrenia or psychotic disorders; dementia) * presence of other neurological diseases or severe clinical as neurodegenerative diseases, severe aphasia, malignancies activity, epilepsy, previous head injury, congestive heart failure or chronic obstructive pulmonary disease stage iii or iv; * presence of severe suicidal ideation (structured planning suicide or attempted suicide in the past 4 weeks); * pregnancy; * inability to provide informed consent; * specific contraindication to tdcs: ( metal plates on the head, anatomic changes.); * in relation to the current use of psychotropic drugs will be permitted, provided they are in doses stable for at least 6 weeks.

Keywords: obsessive-compulsive disorder transcranial direct current stimulation neuromodulation